People: Infinity Pharmaceuticals, Inc. (INFI.O)
INFI.O on Consolidated Issue listed on NASDAQ Global Market
6.11USD
9 Feb 2010
6.11USD
9 Feb 2010
Price Change (% chg)
$-0.07 (-1.13%)
$-0.07 (-1.13%)
Prev Close
$6.18
$6.18
Open
$6.24
$6.24
Day's High
$6.24
$6.24
Day's Low
$6.09
$6.09
Volume
43,041
43,041
Avg. Vol
29,573
29,573
52-wk High
$8.98
$8.98
52-wk Low
$4.77
$4.77
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
| Holtzman, Steven | 55 | 2010 | Executive Chairman of the Board |
| Perkins, Adelene | 50 | 2010 | President, Chief Executive Officer, Chief Business Officer |
| Adams, Julian | 54 | 2007 | Chief Scientific Officer, President - Research & Development |
| Hixson, Harry | 71 | 2006 | Director |
| Venuti, Michael | 55 | 2006 | Director |
| Lander, Eric | 52 | 2006 | Director |
| Moss, Franklin | 60 | 2006 | Director |
| Tananbaum, James | 46 | 2006 | Director |
| Lee, Patrick | 53 | 2006 | Director |
| Levine, Arnold | 69 | 2006 | Director |
| Evnin, Anthony | 68 | 2006 | Director |
| Smith, Ian | 43 | 2008 | Director |
| Babler, Martin | 44 | 2008 | Director |
| Lynch, Thomas | 2009 | Director |
Biographies
| Name | Description |
|---|---|
| Holtzman, Steven | Steven H. Holtzman serves as Executive Chairman of the Board of Infinity Pharmaceuticals, Inc. Mr. Holtzman had served as Chief Executive Officer and as Chair of board of directors of Infinity Pharmaceuticals, Inc. since September 2006, and as President between October 2007 and October 2008. Mr. Holtzman was a co-founder of Old Infinity and served as its Chief Executive Officer and Chair of its board of directors from 2001 until the DPI merger. Mr. Holtzman also served as President of Old Infinity from July 2001 to February 2006. From 1994 to 2001, Mr. Holtzman served as Chief Business Officer of Millennium Pharmaceuticals, Inc., a publicly traded pharmaceutical company. From 1996 to 2001, Mr. Holtzman served as a presidential appointee to the National Bioethics Advisory Commission, the principal advisory body to the President and Congress on ethical issues in the biomedical and life sciences. Prior to joining Millennium Pharmaceuticals, Inc., from 1986 to 1994, Mr. Holtzman was a founder and Executive Vice President of DNX Corporation, a publicly traded biotechnology company. Mr. Holtzman is a director of Anadys Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, and a trustee of the Berklee College of Music. Mr. Holtzman received a B.A. in Philosophy from Michigan State University and a B.Phil. in Philosophy from Oxford University, which he attended as a Rhodes Scholar. |
| Perkins, Adelene | Adelene Q. Perkins, President and Chief Business Officer, has been appointed as Chief Executive Officer of Infinity Pharmaceuticals Inc. effective January 1, 2010. Ms. Perkins is President and Chief Business Officer of Infinity Pharmaceuticals, Inc. since October 2008 and as Executive Vice President and Chief Business Officer between September 2006 and October 2008. Ms. Perkins served as Executive Vice President of Old Infinity from February 2006 until the merger and Chief Business Officer of Old Infinity from June 2002 until the DPI merger. Prior to joining Old Infinity, Ms. Perkins served as Vice President of Business and Corporate Development of TransForm Pharmaceuticals, Inc., a private pharmaceutical company, from 2000 to 2002. From 1992 to 1999, Ms. Perkins held various positions at Genetics Institute, now a business unit of Wyeth Pharmaceuticals, Inc., most recently serving as Vice President of Emerging Business and General Manager of the DiscoverEase ® business unit. From 1985 to 1992, Ms. Perkins held a variety of positions at Bain & Company, a strategy consulting firm. Ms. Perkins received a B.S. in Chemical Engineering from Villanova University and an M.B.A. from Harvard Business School. |
| Adams, Julian | Julian Adams, Ph.D. has served as President of Research & Development and Chief Scientific Officer of Infinity Pharmaceuticals, Inc since October 2007 and as President and Chief Scientific Officer from September 2006 until October 2007. Dr. Adams served as President of Old Infinity from February 2006 until the merger and as Chief Scientific Officer of Old Infinity from October 2003 until the DPI merger. Prior to joining Old Infinity, Dr. Adams served as Senior Vice President, Drug Discovery and Development with Millennium Pharmaceuticals, Inc. from 1999 to 2001. Dr. Adams served as Senior Vice President, Research and Development with LeukoSite Inc., a private biopharmaceutical company, from July 1999 until its acquisition by Millennium in December 1999. Dr. Adams served as a director and Executive Vice President of Research and Development with ProScript, Inc., a private biopharmaceutical company, from 1994 until its acquisition by LeukoSite in 1999. Prior to joining ProScript, Dr. Adams held a variety of positions with Boehringer Ingelheim, a private pharmaceutical company, and Merck & Co., Inc., a publicly traded pharmaceutical company. Dr. Adams received a B.S. from McGill University and a Ph.D. from the Massachusetts Institute of Technology in the field of synthetic organic chemistry. |
| Hixson, Harry | Harry F. Hixson has served as a member of the Board of Directors of Infinity Pharmaceuticals Inc and DPI since May 2001 and as Chairman of DPI from November 2005 though the completion of the reverse merger. Dr. Hixson is currently Chairman of BrainCells, Inc., a private biopharmaceutical company, and served as Chief Executive Officer from its founding until 2005. From 1998 to 2002, Dr. Hixson served as Chief Executive Officer of Elitra Pharmaceuticals, a private biopharmaceutical company, and as its Chairman from 1998 to 2003. Dr. Hixson is also Chairman of SEQUENOM, a publicly-traded human genetics products and services company, and a director of Arena Pharmaceuticals, a publicly-traded pharmaceutical company. Dr. Hixson received a B.S. in Chemical Engineering from Purdue University, an M.B.A. from The University of Chicago and a Ph.D. in Physical Biochemistry from Purdue University. |
| Venuti, Michael | Michael C. Venuti has served as a member of Infinity Pharmaceuticals Inc Board of Directors and the Board of Directors of DPI since May 2003. Dr. Venuti has been Chief Executive Officer of BioSeek, Inc., a privately-held drug discovery company, since November 2007. Prior to that, Dr. Venuti was an Operating Manager at TPG Growth Biotech Ventures, a private equity firm, from January through June 2007. Dr. Venuti served as the Acting Chief Executive Officer of DPI prior to the completion of the reverse merger and as its Chief Scientific Officer from April 2005 through September 2006. Prior to that, he was Senior Vice President of Pharmacogenomics, and was named Senior Vice President of Research and General Manager of Celera South San Francisco when the Celera Genomics Group of Applera Corporation, a life sciences company, acquired Axys Pharmaceuticals, Inc. in 2001. From 1994 through 2001, Dr. Venuti was Director of Medicinal Chemistry, and then Chief Technical Officer, for Axys Pharmaceuticals and its predecessor company, Arris Pharmaceutical Corporation. Dr. Venuti has also held an appointment as Adjunct Professor of Chemistry at the University of California, San Francisco since 1992. Dr. Venuti received an A.B. in Chemistry from Dartmouth College and a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology. |
| Lander, Eric | Eric S. Lander has served as a member of Board of Directors of Infinity Pharmaceuticals Inc since September 2006. Dr. Lander was a co-founder and a member of the board of directors of Old Infinity from 2001 through the completion of the reverse merger. Dr. Lander has been a Professor and Associate Professor of Biology at the Massachusetts Institute of Technology since 1990 and a Professor of Systems Biology at Harvard Medical School since 2004. Dr. Lander has served as the founding Director of The Eli and Edythe L. Broad Institute, a biomedical research institute formed by MIT and Harvard University, since 2003 and as a member of the Whitehead Institute for Biomedical Research since 1989. From 1993 to 2003, Dr. Lander was the Director of the Whitehead/MIT Center for Genome Research. Dr. Lander received an A.B. in Mathematics from Princeton and a D.Phil. in Mathematics from Oxford University, which he attended as a Rhodes Scholar. |
| Moss, Franklin | Franklin H. Moss has served as a member of Board of Directors of Infinity Pharmaceuticals Inc since September 2006. Dr. Moss was a co-founder and a member of the board of directors of Old Infinity from 2001 through the completion of the reverse merger. Since 1998, Dr. Moss has been President of Strategic Software Ventures LLC, a firm that nurtures enterprise software startup companies, and since February 2006, Dr. Moss has served as Director of The Media Lab and Weisner Professor of Media Arts and Sciences at the Massachusetts Institute of Technology. From 2001 through 2003, Dr. Moss served as Chairman of the Informatics Advisory Board of Old Infinity. From 1991 to 1996, Dr. Moss served as Chief Executive Officer and Chairman of Tivoli Systems, a private software company sold to IBM in 1996. Prior to joining Tivoli Systems, Dr. Moss held a variety of positions with Lotus Development, Stellar Computer, Apollo Computer and IBM Research. Dr. Moss received a B.S. in Aerospace and Mechanical Sciences from Princeton University and an S.M. and Ph.D. in Aeronautics and Astronautics from the Massachusetts Institute of Technology. |
| Tananbaum, James | Mr.Tananbaum has served as a member of board of directors since September 2006. Dr. Tananbaum was a co-founder and a member of the board of directors of Old Infinity from 2001 through the completion of the reverse merger. From 2000 to the present, Dr. Tananbaum has served as Managing Director of Prospect Venture Partners LP II and III, venture partnerships he co-founded. From 1997 to 2000, Dr. Tananbaum served as Chief Executive Officer of Theravance, Inc., a publicly traded biopharmaceutical company. From 1993 to 1997, Dr. Tananbaum served as a partner of Sierra Ventures, a venture capital firm. Dr. Tananbaum also serves as a director of Jazz Pharmaceuticals, Inc. and Novavax, Inc., both publicly-held biopharmaceutical companies, and the following privately-held biopharmaceutical companies: Vitae Pharmaceuticals, Inc., Patient Care, Inc., Pathwork Diagnostics, Inc., RoxRo Pharma, Inc., Cognentus Pharmaceuticals, Inc., Amira Pharmaceuticals, Inc. and Lapis Therapeutics, Inc. Dr. Tananbaum received a B.S.E.E. from Yale University and an M.D. and M.B.A. from Harvard University. |
| Lee, Patrick | Patrick P. Lee has served as a member of Board of Directors of Infinity Pharmaceuticals Inc since September 2006 and a member of the board of directors of Old Infinity from September 2002 through the completion of the reverse merger. Mr. Lee is a General Partner of Advent Venture Partners, a venture capital firm, and has been employed by Advent Venture Partners since 1999. Prior to joining Advent Venture Partners, from 1989 to 1999, Mr. Lee held various positions with Rhone-Poulenc Rorer in the U.S., and Rhone Poulenc in Paris, France, where he was most recently Group Vice President for Mergers & Acquisitions. Prior to that he had been with Baxter International and Booz Allen and Hamilton. Mr. Lee serves as a director of Algeta AS, a publicly-held biopharmaceutical company and the following privately-held biopharmaceutical companies: Rhytec Ltd., Conatus, Inc. and Specialty European Pharma, Ltd. Mr. Lee received a B.A. in Biology from Vassar College and an M.B.A. from the Stanford Graduate School of Business. |
| Levine, Arnold | Arnold J. Levine has served as a member of Board of Directors of Infinity Pharmaceuticals Inc since September 2006 and a member of the board of directors of Old Infinity from 2001 through the completion of the reverse merger. Since 2002, Dr. Levine has been a Professor at The Cancer Institute of New Jersey, Robert Wood Johnson School of Medicine and a Professor at the Institute for Advanced Study. From 1998 to 2002, Dr. Levine was President of Rockefeller University. Prior to joining Rockefeller University, Dr. Levine was the Harry C. Weiss Professor in the Life Sciences and Chairman of the Department of Molecular Biology at Princeton University from 1984 to 1996. Dr. Levine also serves as a director of Theravance, Inc., and Applera Corporation, publicly-traded life science companies. Dr. Levine received a B.A. in Biology from Harpur College, State University of New York at Binghamton and a Ph.D. in Microbiology from The University of Pennsylvania. |
| Evnin, Anthony | Anthony B. Evnin has served as a member of Board of Directors of Infinity Pharmaceuticals Inc since September 2006 and a member of the board of directors of Old Infinity from June 2001 through the completion of the reverse merger. Since 1980, Dr. Evnin has served as Managing General Partner of Venrock Associates, a venture capital firm, and has been employed by Venrock Associates since 1974. Dr. Evnin also serves as a director of several private companies, as well as the following publicly-traded biopharmaceutical companies: Icagen, Inc., Memory Pharmaceuticals Corp., Renovis, Inc. and Sunesis Pharmaceuticals, Inc. Dr. Evnin received an A.B. in Chemistry from Princeton University and a Ph.D. in Chemistry from the Massachusetts Institute of Technology. |
| Smith, Ian | Ian F. Smith is Director of Infinity Pharmaceuticals Inc since May 2008. Mr. Smith is Executive Vice President and Chief Financial Officer of Vertex Pharmaceuticals, Inc., a position he has held since February 2006. From November 2003 to February 2006, he was Vertex’s Senior Vice President and Chief Financial Officer, and from October 2001 to November 2003, he served as Vertex’s Vice President and Chief Financial Officer. Prior to joining Vertex, Mr. Smith served as a partner in the Life Science and Technology Practice Group of Ernst & Young LLP, an accounting firm, from 1999 to 2001. Mr. Smith initially joined Ernst & Young’s U.K. firm in 1987, and then joined its Boston office in 1995. Mr. Smith currently is a member of the Board of Directors of Acorda Therapeutics, Inc., and Epix Pharmaceuticals, Inc., both publicly-traded biopharmaceutical companies. Mr. Smith holds a B.A. in accounting and finance from Manchester Metropolitan University, U.K., is a member of the American Institute of Certified Public Accountants and is a Chartered Accountant of England and Wales. |
| Babler, Martin | Martin Babler is Director of Infinity Pharmaceuticals Inc since May 2008. Mr. Babler is Chief Executive Officer of Talima Therapeutics, Inc., a privately-held drug delivery company, a position he has held since February 2008. Prior to joining Talima, from 2000 to 2006, Mr. Babler was Vice President of Immunology Sales and Marketing, and Director of Cardiovascular Marketing, at Genentech, Inc. Prior to joining Genentech, Mr. Babler held various roles of increasing responsibility in sales, sales management, marketing and business development with Eli Lilly and Company. Mr. Babler holds a degree in Pharmacy/Pharmacology from the ETH in Zurich, Switzerland and attended the Executive Development Program at Kellogg Graduate School of Management. |
| Lynch, Thomas | Dr. Thomas J. Lynch, Jr., M.D., is Director of Infinity Pharmaceuticals, Inc. Dr. Lynch is the Director of the Yale Cancer Center and the Physician-in-Chief at Smilow Cancer Hospital at Yale-New Haven. He has focused his career on the care and treatment of patients with lung cancer and the clinical development of novel agents targeting lung cancer. Recently, his work has focused on agents directed against the epidermal growth factor receptor (EGFR) and the potential role that EGFR mutations play in lung cancer biology. Prior to 2009, Dr. Lynch was the Chief of Hematology-Oncology at Massachusetts General Hospital (MGH) and a Professor of Medicine at Harvard Medical School. He received his M.D. from Yale University and completed his internship and residency at MGH. Before joining the staff at MGH, Dr. Lynch served as a fellow in medical oncology at the Dana-Farber Cancer Institute. Dr. Lynch is a founding board member and vice chair of the board of the Kenneth B. Schwartz Center, a foundation devoted to promoting compassionate health care. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
| Holtzman, Steven | 1,561,710 |
| Perkins, Adelene | 1,222,210 |
| Adams, Julian | 1,196,820 |
| Hixson, Harry | -- |
| Venuti, Michael | 1,589,920 |
| Lander, Eric | -- |
| Moss, Franklin | -- |
| Tananbaum, James | -- |
| Lee, Patrick | -- |
| Levine, Arnold | -- |
| Evnin, Anthony | -- |
| Smith, Ian | -- |
| Babler, Martin | -- |
| Lynch, Thomas | -- |
As Of 30 Dec 2008
Options Compensation
| Name | Options | Value |
|---|---|---|
| Holtzman, Steven | 74,928 | 135,288 |
| Perkins, Adelene | 0 | 0 |
| Adams, Julian | 104,836 | 193,376 |
| Hixson, Harry | 0 | 0 |
| Venuti, Michael | 40,000 | 0 |
| Lander, Eric | 0 | 0 |
| Moss, Franklin | 0 | 0 |
| Tananbaum, James | 0 | 0 |
| Lee, Patrick | 0 | 0 |
| Levine, Arnold | 0 | 0 |
| Evnin, Anthony | 0 | 0 |
| Smith, Ian | 0 | 0 |
| Babler, Martin | 0 | 0 |
| Lynch, Thomas | 0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
| LEE PATRICK PAK TIN | 5,499 | $0.00 |
| LEE PATRICK PAK TIN | 152,889 | $0.00 |
| LEE PATRICK PAK TIN | 18,331 | $0.00 |
| LEE PATRICK PAK TIN | 77,728 | $0.00 |
| LEE PATRICK PAK TIN | 568,663 | $0.00 |
| LEE PATRICK PAK TIN | 21,998 | $0.00 |
| LEE PATRICK PAK TIN | 278,648 | $0.00 |
| ROSEBAY MEDICAL CO L P | 1,000,000 | $15.00 |
| BEACON CO | 1,000,000 | $15.00 |
| PERKINS ADELENE Q | 2,100 | $8.00 |
| PERKINS ADELENE Q | 198 | $7.90 |
| PERKINS ADELENE Q | 100 | $7.95 |
| PERKINS ADELENE Q | 100 | $7.93 |
| PERKINS ADELENE Q | 100 | $7.99 |
| PERKINS ADELENE Q | 2,000 | $7.90 |
| PERKINS ADELENE Q | 1,043 | $7.95 |
| PERKINS ADELENE Q | 1,000 | $7.96 |
| PERKINS ADELENE Q | 239 | $7.91 |
| PERKINS ADELENE Q | 200 | $7.96 |
| PERKINS ADELENE Q | 420 | $7.88 |
| PERKINS ADELENE Q | 1,000 | $7.94 |
| PERKINS ADELENE Q | 100 | $7.42 |
| PERKINS ADELENE Q | 600 | $7.41 |
| PERKINS ADELENE Q | 100 | $5.70 |
| PERKINS ADELENE Q | 1,820 | $6.00 |
© Copyright 2010 Thomson Reuters
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
